Biological predictors of response to radiotherapy in head and neck cancer: Recent advances and emerging perspectives

Tumori

Volumn 87, Issue 6, 2001, Pages 355-363

  Corvò, Renzo ^a   Antognoni, Paolo ^a   Sanguineti, Giuseppe ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Head and neck cancer; Prediction of response; Radiotherapy

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; CELL DNA; CYCLIN D1; CYCLINE; KI 67 ANTIGEN;

ANGIOGENESIS; APOPTOSIS; CANCER RADIOTHERAPY; CELL CYCLE; CELL INTERACTION; CELL KINETICS; HEAD AND NECK CANCER; HEMOGLOBIN DETERMINATION; HUMAN; ONCOGENE; OXYGENATION; PLOIDY; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; BIOLOGICAL ACTIVITY; CANCER CONTROL; CELL COUNT; CELL CYCLE REGULATION; CELL HYPOXIA; CELL PROLIFERATION; GENE PRODUCT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HETEROZYGOSITY LOSS; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME;

EID: 0035746349     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160108700601     Document Type: Review

References (69)

1. Confirmation of improved local-regional control with altered fractionation in head and neck cancer
2. Dose, volume and tumor-control predictions in radiotherapy
3. Predictive assays: Will they ever have a role in the clinic?
4. Molecular markers predictive of response and prognosis in the patients with advanced squamous cell carcinoma of the head and neck: Evolution of a model beyond TNM staging
5. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen
6. Modulation of molecular targets to enhance radiation
7. Blood pressure and hemoglobin concentration: Multivariate analysis of local control after irradiation for head and neck cancer
8. Using the TNM system to predict survival in squamous cell carcinoma of the head and neck
9. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemotherapy
10. Selection of markers to predict tumor response or survival: Description of a novel approach
11. The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancer
12. Tumor radiosensitivity: It's the subpopulations that count
13. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy
14. Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers
15. Assessment of cell proliferation by AgNOR scores and Ki-67 labeling indices and a comparison with potential doubling times
16. Proliferating cell nuclear antigen (PCNA) expression and nuclear DNA content in predicting recurrence after radiotherapy of early glottic cancer
17. Flow cytometric quantification of the proliferation-associated nuclear antigen p105 DNA content in advanced head and neck cancer: Results of RTOG 91-08
18. Argyrophilic nucleolar organizer region counts and prognosis in pharyngeal carcinoma
19. Predictive value of tumor cell kinetics parameters in radiotherapy: Considerations regarding data production and analysis
20. The value of cell kinetics parameters as predictors for radiotherapy outcome in head and neck cancer: A multicenter analysis
21. Potential doubling time in head and neck tumors treated by primary radiotherapy: Preliminary evidence for a prognostic significance in local control
22. Tpot and head and neck cancer: Where are we now?
23. Can Ki-67 immuno-staining predict response to radiotherapy in oral squamous cell carcinoma
24. The predictive role of flow-cytometry derived tumor potential doubling time (Tpot) in radiotherapy. Open questions and future perspectives
25. Is there a future for cell kinetics measurements using IdUrd or BdUrd?
26. Reproducibility of measurements of potential doubling time of tumor cells in the multicentre National Cancer Institute protocol T92-00045
27. What Tpot is not
28. Cell kinetics changes in human squamous cell carcinoma during radiotherapy study using in vivo administration of two halogenated pyrimidines
29. Tumor proliferation, p53 expression and apoptosis in laryngeal carcinoma. Relation to the results of radiotherapy
30. Measurement of tumor oxygenation
31. Measurement of human tumor oxygenation status by a polarographic needle electrode
32. Interrelationship of proliferation and hypoxia in carcinoma of the cervix
33. Pre-treatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
34. Tumor hypoxia is prognostic of survival in patients with advanced head and neck carcinoma treated by radiotherapy: An international multi-centre study
35. The tumor volume and clonogen number relationship: Tumor control predictions based upon tumor volume estimated from computed tomography
36. The influence of microenvironmental factors during cancer therapy
37. Coculture with human fibroblasts increases the radiosensitivity of MCF-7 mammary carcinoma cells in collagen gels
38. The clinical status of Tpot as a predictor. Or why no tempest in Tpot!
39. Interrelationships of DNA-ploidy and cell proliferation markers with T-stage and N-stage in primary laryngeal tumors
40. Transmutability of dose and time. Commentary on the first report of RTOG 90003
41. Tumor heterogeneity, tumor size and radioresistance
42. Radiation-induced DNA double-strand break frequencies in human squamous cell carcinoma cell lines of different radiation sensitivities
43. Genetic markers for radiosensitivity
44. The prediction of human tumor radiosensitivity in situ: An approach using chromosome aberrations detected by fluorescence in situ hybridization
45. The role of the H-ras oncogene in radiation resistance and metastases
46. Angiogenesis vs response after combined chemoradiotherapy of squamous cell head and neck carcinoma
47. Intratumor microvessels density as a prognostic factor in cancer
48. Vascular endothelial growth factors as a target for antiangiogenic therapy
49. Is p53 a marker of radioresistance in head and neck cancer? A laboratory-correlative study from RTOG 90-03
50. Influence of p53 and bcl-2 on proliferative activity and treatment outcome in head and neck cancer patients
51. Bcl-2 expression in head and neck cancer: An enigmatic prognostic marker
52. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma
53. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer
54. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53
55. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head and neck cancer treated by radiotherapy
56. Interaction between potential doubling time and TP53 mutation: Predicting radiotherapy outcome in squamous cell carcinoma of the head and neck
57. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
58. Combined effects of angiostatin and ionizing radiation in antitumor therapy
59. Cyclooxygenase-2 inhibitors in tumorigenesis
60. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis
61. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme
62. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression
63. Combined response following treatment with IMC-C224, an EGFR MoAB combined with radiotherapy in advanced head and neck cancer
64. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation
65. New therapeutic agent targeting the epidermal growth factor receptor
66. Hamming clustering techniques for the identification of prognostic indices in patients with advanced head and neck cancer treated with radiation therapy
67. Accelerated radiation therapy for locally advanced squamous cell carcinoma of the oral cavity and oropharynx selected according to tumor cell kinetics. A phase II multicenter study
68. Novel molecular target for tumor radiosensitization
69. Therapeutic targets in radiotherapy